Your AI-Trained Oncology Knowledge Connection!
Video
Author(s):
Mario Sznol, MD, discusses the adverse events that can occur from nivolumab in combination with ipilimumab for patients with melanoma.
Mario Sznol, MD, professor of medicine, co-director, Yale SPORE in Skin Cancer, Yale Cancer Center, discusses the adverse events (AEs) that can occur from nivolumab (Opdivo) in combination with ipilimumab (Yervoy) for patients with melanoma.
The most common AEs include skin rash, endocrine toxicities, and are gastrointestinal-related. These therapies that are often used in melanoma can affect any organ and physicians should be aware of pneumonitis, nephritis, arthralgia, myositis, and central nervous system toxicities, says Sznol. Liver function test elevation and endocrinopathies, such as thyroiditis and pituitary dysfunction, can also occur.
These AEs are important to note when patients are receiving an anti—PD-1 agent in combination with an anti–CTLA-4 agent, Sznol concludes.
Jun 5th 2025 - Jul 12th 2025
Jun 5th 2025 - Jul 12th 2025
Jun 5th 2025 - Jul 12th 2025
Jun 6th 2025 - Jul 12th 2025
Jun 6th 2025 - Jul 12th 2025
Jun 5th 2025 - Jul 12th 2025
Jun 5th 2025 - Jul 12th 2025
Jun 5th 2025 - Jul 12th 2025
Jun 6th 2025 - Jul 12th 2025
Jun 6th 2025 - Jul 12th 2025
Jun 5th 2025 - Jul 12th 2025
Jun 5th 2025 - Jul 12th 2025
Jun 5th 2025 - Jul 12th 2025
Pirtobrutinib Improves Patient-Reported Outcomes in Relapsed/Refractory CLL/SLL
MAIC Analysis Shows PFS Favorability With Zanubrutinib vs Acalabrutinib/Venetoclax in CLL
Isa-KRd Yields Prolonged MRD Negativity vs KRd in Newly Diagnosed Myeloma
Elranatamab Triplet Yields Nearly 100% ORR in Newly Diagnosed Multiple Myeloma
2 Commerce Drive
Cranbury, NJ 08512